Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Revenue of $3.14M

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.

Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• AeroVironment sets FY27 revenue guidance and FY30 financial targets
• Keurig Dr Pepper (KDP) PT Raised to $39 at Bernstein SocGen Group